• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Upadacitinib plus topical corticosteroids is safe and effective for moderate-to-severe atopic dermatitis;

bySuchita Nety
June 24, 2021
in StudyGraphics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Upadacitinib combined with topical corticosteroids reduced Eczema Area and Severity Index (EASI) and Investigator’s Global Assessment for atopic dermatitis (vIGA-AD) scores significantly more than placebo with corticosteroids.

2. Efficacy of upadacitinib combination therapy was comparable to upadacitinib monotherapy, suggesting potential for steroid-sparing treatment of atopic dermatitis.

Evidence Rating Level: 1 (Excellent)

Study Rundown: For patients with moderate-to-severe atopic dermatitis (eczema), topical corticosteroids combined with systemic therapy is typically the first line treatment regimen. Upadacitinib is an oral JAK inhibitor used to treat immune-mediated inflammatory conditions that is currently being investigated for the treatment of atopic dermatitis. This randomized, double-blind, placebo-controlled, phase 3 clinical trial (AD Up) evaluated the safety and efficacy of Upadacitinib (15 mg or 30 mg) combined with topical corticosteroid therapy compared to placebo combination therapy for the treatment of atopic dermatitis for 16 weeks. Treatment response was measured using 75% reduction in EASI score from baseline (EASI-75) and vIGA-AD response scores of 0 (clear) or 1 (almost clear) with at least two grades of improvement compared to baseline. Secondary endpoints included score changes assessed at various time points during the study. Treatment response to Upadacitinib 15 mg and 30 mg with topical corticosteroids were superior to placebo with topical corticosteroids at the end of 16 weeks, with over 65% of patients achieving an EASI-75 response and over 40% vIGA-AD response. Patients were also able to discontinue corticosteroid use over the course of the study. Both treatment regimens were well tolerated, with severe adverse events reported for <1% of the study population. Common adverse effects included acne, nasopharyngitis, and upper respiratory infection. The results of this trial demonstrate the efficacy and safety of two doses of Upadacitinib plus topical corticosteroids for the treatment of atopic dermatitis, encouraging future studies on Upadacitinib-based steroid-sparing treatment regiments.

Click to read the study in The Lancet

Relevant Reading: Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial

In-Depth [randomized controlled trial]: This clinical trial was conducted at 171 clinical centers across 22 countries. 901 patients with moderate-to-severe atopic dermatitis, defined as ≥10% of body surface area, EASI score ≥16, and vIGA-AD score ≥3). Patients were randomly assigned 1:1:1 to two treatment groups (Upadacitinib 15 mg [n=300] or 30 mg [n=297] plus topical corticosteroids) or placebo group (placebo plus topical corticosteroids; n=304) for a 16-week treatment period. Treatment was given orally once daily, and patients were assessed for corticosteroid discontinuation as symptoms stabilized. At 16 weeks, a significantly greater proportion of patients in both upadacitinib groups achieved a EASI-75 and vIGA-AD response compared to placebo. The adjusted difference in EASI-75 response for the 15 mg treatment group was 38.1% (95% CI 30.8 – 45.4, p<0.0001) and 50.6% (43.8 – 57.4, p<0.0001) for the 30 mg group. The adjusted difference in vIGA-AD response for the 15 mg treatment group was 28.5% (22.1 – 34·9, p<0.0001) and 47.6% (41.1 – 54.0, p<0.0001) for the 30 mg treatment group. Additionally, the median time to first discontinuation of topical steroids was shorter in both treatment groups compared to placebo (15 mg median 88 days IQR [73–not estimable], 30 mg median 57 days [41–59], placebo median not estimable [120–not estimable], p <0.0001 for both treatment groups). No deaths were reported in either treatment group, with severe adverse reactions that resulted in treatment discontinuation occurring for only 1% of patients. The results of this trial are limited by the 16-week follow-up period, as atopic dermatitis requires long-term systemic management. However, this trial provides compelling evidence for the efficacy of Upadacitinib as a systemic therapy for the treatment atopic dermatitis, both in reducing disease burden and reducing the need for topical corticosteroids.

RELATED REPORTS

#VisualAbstract: Addition of itacitinib to corticosteroids did not show clinical benefit over placebo in initial treatment of acute graft-versus-host disease

#VisualAbstract: The use of COVID-19 convalescent plasma not beneficial to patients hospitalized with COVID-19

Corticosteroid use may not offer benefit for children with acute orbital cellulitis

 

Tags: atopic dermatitiscorticosteroidsdermatitistopical corticosteroidsupadacitinib
Previous Post

Real-time continuous glucose monitoring improves glycemic control compared to intermittently scanned monitoring for patients with type 1 diabetes

Next Post

#VisualAbstract: Preterm formula is similarly effective to human milk fortifiers as breastmilk supplement

RelatedReports

#VisualAbstract: Addition of itacitinib to corticosteroids did not show clinical benefit over placebo in initial treatment of acute graft-versus-host disease
StudyGraphics

#VisualAbstract: Addition of itacitinib to corticosteroids did not show clinical benefit over placebo in initial treatment of acute graft-versus-host disease

January 6, 2022
#VisualAbstract: Pericardiotomy after cardiac surgery may reduce the incidence of postoperative atrial fibrillation
StudyGraphics

#VisualAbstract: The use of COVID-19 convalescent plasma not beneficial to patients hospitalized with COVID-19

December 23, 2021
Adalimumab aids in control of noninfectious uveitis
Infectious Disease

Corticosteroid use may not offer benefit for children with acute orbital cellulitis

October 26, 2021
#VisualAbstract Dupilumab may contribute to ocular surface disease in patients with atopic dermatitis
StudyGraphics

#VisualAbstract Dupilumab may contribute to ocular surface disease in patients with atopic dermatitis

September 10, 2021
Next Post
#VisualAbstract: Preterm formula is similarly effective to human milk fortifiers as breastmilk supplement

#VisualAbstract: Preterm formula is similarly effective to human milk fortifiers as breastmilk supplement

A prospective evaluation of clinical HEART score agreement, accuracy, and adherence in emergency department chest pain patients

Digital imaging detects sight-threatening retinopathy of prematurity

Fetoscopic endoluminal tracheal occlusion improves infant survival for congenital diaphragmatic hernia

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Pretreatment with radiotherapy and two cycles of concurrent cisplatin may reduce toxicity in locally advanced nasopharyngeal carcinoma
  • High pediatric sequential organ failure assessment (pSOFA) score may predict hospital mortality in emergency department setting
  • #VisualAbstract: Increased physical activity is a long-term protective factor for dementia
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.